Recent guidance on drug-drug interaction (DDI) testing recommends evaluation of circulating metabolites. However, there is little consensus on how to quantitatively predict and/or assess the risk of in vivo DDIs by multiple time-dependent inhibitors (TDIs), including metabolites from in vitro data. Fluoxetine was chosen as the model drug to evaluate the role of TDI metabolites in DDI prediction because it is a TDI of both CYP3A4 and CYP2C19 with a circulating N- 
TDIs possess an in vivo circulating N-dealkylated metabolite that can also inactivate P450s (VandenBrink and Isoherranen, 2010 ), but only a few studies have examined the role of these metabolites in in vivo DDIs. Two models have been evaluated to improve upon the underprediction of in vivo CYP3A4 inhibition using diltiazem and verapamil and their N-dealkylated metabolites as models. In these models the TDI kinetics of the parent and metabolite were either summed up to predict total time-dependent inhibition (Wang et al., 2004; Rowland Yeo et al., 2010) or a mutual in vivo inhibitor-inhibitor interaction component was incorporated to predict in vivo interaction (Zhang et al., 2009b) . Both models demonstrated improved prediction accuracy with the inclusion of metabolite time-dependent inhibition when compared to parent alone suggesting that incorporation of multiple inhibitors into TDI predictions and risk assessment is necessary.
The aim of this study was to establish how multiple inhibitor systems, that include timedependent inhibition, can be incorporated into DDI risk assessment. The secondary alkylamine fluoxetine was used as a model because it is a complex multiple P450 inhibitor. Fluoxetine provides both a model of a metabolite-parent pair and enantiomer mixture that incorporates
7 combinations of time-dependent and reversible inhibition with multiple P450s. Fluoxetine, and its circulating metabolite, norfluoxetine, are present as mixtures of stereoisomers in vivo. The (S)-enantiomers circulate at 210% -280% of the (R)-enantiomers, and norfluoxetine enantiomers at 150% -180% of fluoxetine enantiomers (Jannuzzi et al., 2002) , hence meeting the FDA criteria for metabolite testing. In vitro, (R)-and (S)-fluoxetine are TDIs of CYP2C19 (Stresser et al., 2009 ) and racemic fluoxetine is a TDI of CYP3A4 (Mayhew et al., 2000) .
Racemic norfluoxetine causes an IC 50 shift with CYP2C19 (Stresser et al., 2009 ) and appears to inhibit CYP3A4 reversibly (von Moltke et al., 1996) . In this study, fluoxetine and norfluoxetine were stereoselectively characterized as CYP2C19 and CYP3A4 TDIs. The contribution of norfluoxetine to the predicted DDI was determined for each P450 and the prediction of multiple TDIs between CYP2C19 and CYP3A4 was compared.
9 initially present but aliquots were diluted 10-fold into wells containing 1 mM NADPH and substrate after 0.25, 10, 20 and 30 minutes. In the pooled HLM incubation experiments, < 10% of inhibitor depletion and negligible accumulation of norfluoxetine (< 6% of fluoxetine initial concentration) under the incubation conditions was confirmed. All pooled HLM incubations with substrate proceeded for 3 min (midazolam), and 15 min ((S)-mephenytoin) before quenching with an equal volume acetonitrile containing 100 nM internal standard. The inhibitor concentration at 50% maximum inhibition (IC 50 ) was determined by the equation:
where v I and v 0 are the velocity of product formation at a given inhibitor concentration (I) or without the presence of inhibitor, respectively. The time-dependent inhibition affinity (K I ) and apparent maximum time-dependent inhibition rate (k inact,app ) were determined by the equation:
and either centrifuged at 440,000 x g for 90 min at 37 °C or incubated for 90 min at 37 °C as previously described (Templeton et al., 2010 ). An aliquot was removed from both tubes and an equal volume of acetonitrile was added, the samples were centrifuged at 3000 x g for 15 min and the supernatant was used for analysis. The f u,HLM or f u,plasma was determined as the quotient of determined inhibitor concentration with and without centrifugation.
Quantitation of analytes. Concentrations of 1-hydroxymidazolam, (S)-4-hydroxymephenytoin,
(R)-fluoxetine, (S)-fluoxetine, (R)-norfluoxetine and (S)-norfluoxetine were analyzed using a Shimadzu Prominence UHPLC (Tokyo, Japan) coupled to an AB Sciex API 3200 MS/MS (Framingham, MA, USA). All analytes were separated using an Agilent Zorbax Eclipse XDB 2.1
x 50 mm, 5 µm column (Santa Clara, CA, USA) with a linear gradient elution from 95% water with 0.1% formic acid:5% acetonitrile to 50% acetonitrile over 3 minutes, 95% acetonitrile for 2 minutes, then allowed to re-equilibrate to initial conditions for 2 minutes. All analytes were detected using positive electrospray ionization with a source temperature of 500 °C, Ionization voltage of 5500 V and curtain gas, collisionally activated dissociation gas, source gas 1 and 
Additionally, the same data were simulated using an equation that incorporates competitive reversible inhibitor-inhibitor interaction (inhibitor-inhibitor interaction model):
The unbound FDA R-value for assessing in vivo CYP2C19 and CYP3A4 DDI risk due to reversible (Equation 6) or time-dependent inhibition (Equation 7) was predicted: (Ghanbari et al., 2006; Obach et al., 2007) . The change in the concentration of active enzyme in vivo in the presence of multiple TDIs was predicted using two models, additive and inhibitor-inhibitor interaction models (Zhang et al., 2009b; Rowland Yeo et al., 2010) : Table 1 ). The K I value for (R)-fluoxetine was 75% lower than any of the other three compounds studied. Reversible IC 50 values against CYP2C19 were also determined in pooled HLMs (Table 1 ) was a more efficient
norfluoxetine enantiomers were less efficient at inactivating CYP3A4 than CYP2C19.
Interestingly, the most efficient TDIs of CYP2C19 in HLMs were (R)-fluoxetine and (S)-norfluoxetine, whereas these two compounds were the ones that did not inactivate CYP3A4.
The reversible IC 50 values for each enantiomer against CYP3A4 in pooled HLMs were also determined (Table 1 (Table 3 ). The I max value used was the maximum unbound plasma concentration (f u,p *I max ) for each of the four compounds after 8 daily oral doses of 60 mg rac-fluoxetine (Bergstrom et al., 1992; Jannuzzi et al., 2002) . For both CYP2C19 and CYP3A4, reversible inhibition was predicted to be unlikely in vivo (I max /IC 50 < 0.1), with the maximum predicted I max /IC 50 value of 0.03 for (R)-fluoxetine against CYP2C19 (Table 3) . Both fluoxetine and norfluoxetine enantiomers are predicted to result in in vivo timedependent inhibition of CYP2C19 (λ/k deg > 0.1), with (S)-norfluoxetine predicted to result in the greatest magnitude of in vivo inhibition between the four inhibitors (λ/k deg = 9.4) ( Table 3) (Table 4) . For both CYP2C19 and CYP3A4, the predicted inhibition was not different between the additive and the inhibitor-inhibitor interaction models.
This similarity can be explained by the fact that in vivo unbound plasma I max concentrations are at least 30-fold below the in vitro determined unbound IC 50 values (I max /IC 50 ≤ 0.03) ( Table 3) .
Summation of effects of all four inhibitors yields a λ /k deg of 20 and 2.5 -2.6 for CYP2C19 and
17 of fluoxetine and norfluoxetine. The aim was to determine what inhibitor conditions would differentiate the two models in vivo and indicate which model is more prudent to use for risk assessment of multiple TDI systems. In both multiple TDI systems, the fold prediction difference increased as either inhibitor in the system increased in I max /IC 50 . This discrepancy between the additive and inhibitor-inhibitor interaction models was more pronounced with the combination of (R)-fluoxetine with (R)-norfluoxetine than with the combination of (S)-fluoxetine and (S)-norfluoxetine (maximum fold prediction difference under the simulated conditions of 3.2-fold versus 2.6-fold). Sensitivity analysis revealed that this difference between systems is not due to the overall magnitude of predicted interaction, but is directly proportional to the differences in magnitude of k inact,app between parent and metabolite: the quotient of (R)-norfluoxetine and (R)-fluoxetine or (S)-norfluoxetine and (S)-fluoxetine k inact,app values is 2.9 and 1.1, respectively. To demonstrate this relationship, a generic metabolite and parent inhibitor pair was simulated where the parent k inact,app was 10-fold larger than the metabolite k inact,app (Panel C). In this generic example, prediction differences up to 6.8-fold between the additive and inhibitor-inhibitor interaction models were calculated, indicating the possibility of significant differences in in vivo risk assessment between the two models when I max > IC 50 for both inhibitors and the inhibitor k inact,app values are very different. This difference in the prediction accuracy between the models illustrates the importance in determining TDI parameters for both the metabolites and the parent drug as independent inhibitors to refine the in vitro-to-in vivo prediction models. than that of (R)-norfluoxetine. Norfluoxetine enantiomers were predicted to be responsible for about 60% of the in vivo CYP2C19 inhibition. The importance of both norfluoxetine enantiomers in overall predicted CYP2C19 inhibition highlights the need to evaluate models for risk prediction of multiple TDIs simultaneously.
Two partially overlapping models for in vitro-to-in vivo prediction of DDIs due to multiple TDIs exist (Zhang et al., 2009b; Rowland Yeo et al., 2010) . In vitro-to-in vitro predictions were done to evaluate the applicability of the additive (Equation 4) and inhibitor-inhibitor interaction (Equation 5) models in describing the effect of multiple TDIs in P450 activity. The comparison of the models showed that at low inhibitor concentrations there were no differences between the two models but significant differences were observed at inhibitor concentrations above K I . Both models predicted the observed decrease in CYP2C19 activity well at low concentrations of the enantiomer mixtures, but did not predict the combination of the metabolite and parent. At high inhibitor concentrations only the inhibition of CYP2C19 by norfluoxetine enantiomers could be predicted and only using the inhibitor-inhibitor interaction model. Overall, the additive model
fluoxetine, there were no differences in in vitro-to-in vivo predictions between the two models (Table 4 ). The lack of differences between the models is due to the fact that none of the inhibitors circulate at concentrations in vivo that are required to cause significant reversible inhibition of the P450 of interest since Equation 9 system with two TDIs indicates that less than 2-fold difference between models will be observed when I max /IC 50 < 1 for both inhibitors. Some TDIs, such as ritonavir (Luo et al., 2003) and amprenavir (Ernest et al., 2005) , circulate at concentrations above their in vitro inhibition affinity constants (Hsu et al., 1998; Polk et al., 2001 ) and hence, significant differences in risk assessment between the two models would be expected, but only if the k inact,app values are significantly different for the independent inhibitors. In this situation, use of the inhibitor-inhibitor interaction model may be more accurate, but the additive model will always predict a larger in vivo DDI (i.e. a worst-case scenario) and hence, may be more appropriate for in vivo DDI risk assessment of multiple TDI systems.
In conclusion, the results of this study show that in vitro, both fluoxetine and norfluoxetine are stereoselective TDIs of CYP2C19 and CYP3A4 and that norfluoxetine is predicted to play an equal or greater role in in vivo CYP2C19 and CYP3A4 DDIs than fluoxetine.
Worst-case scenario risk assessment for in vivo DDI liability of multiple TDI systems can be achieved by incorporating in vitro time-dependent inhibition information for both parent and metabolite (determined independently and stereoselectively when applicable) and predicted using a simple additive model of λ /k deg, but this methodology will likely quantitatively over-predict the magnitude of in vivo DDIs. The results of this study indicate that better understanding of TDI mechanism is necessary for quantitative prediction of DDIs and hence, qualitative TDI risk assessment may be more appropriate at this time. Furthermore, these results provide insight into how circulating metabolites could be accounted for in in vivo DDI risk assessment for TDIs during new drug development, but emphasize the need for further research to determine the most appropriate methodology and models to use for prediction of multiple TDI systems. 
